Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 1 | 62.8% | +36.0% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
| KUCKLA, ANNA GRACE | 1 | 51.3% | +52.1% |
| ENGLISH, CONNOR KENNEDY | 1 | 55.9% | +55.6% |
| RODRIGUEZ, RAYNA B | 1 | 32.4% | +21.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 24d overdue |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 8d overdue |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 19308925 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | TRAN, SUSAN T | 27d |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 42d |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1615 | 1 |
| 1626 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19308925 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | TRAN, SUSAN T | 1615 | §103 | Final Rejection | 27d | Pending | Aug 25, 2025 |
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 24d overdue | Pending | Sep 11, 2023 |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 42d | Pending | Aug 29, 2023 |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Non-Final OA | 8d overdue | Pending | Dec 09, 2022 |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | 12d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial